These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
195 related articles for article (PubMed ID: 18821707)
1. Epigallocatechin-3-gallate diminishes CCL2 expression in human osteoblastic cells via up-regulation of phosphatidylinositol 3-Kinase/Akt/Raf-1 interaction: a potential therapeutic benefit for arthritis. Lin SK; Chang HH; Chen YJ; Wang CC; Galson DL; Hong CY; Kok SH Arthritis Rheum; 2008 Oct; 58(10):3145-56. PubMed ID: 18821707 [TBL] [Abstract][Full Text] [Related]
2. Oncostatin M-induced CCL2 transcription in osteoblastic cells is mediated by multiple levels of STAT-1 and STAT-3 signaling: an implication for the pathogenesis of arthritis. Kok SH; Hong CY; Kuo MY; Wang CC; Hou KL; Lin YT; Galson DL; Lin SK Arthritis Rheum; 2009 May; 60(5):1451-62. PubMed ID: 19404962 [TBL] [Abstract][Full Text] [Related]
3. Epigallocatechin-3-gallate diminishes cytokine-stimulated Cyr61 expression in human osteoblastic cells: a therapeutic potential for arthritis. Wu PH; Lin SK; Lee BS; Kok SH; Wang JH; Hou KL; Yang H; Lai EH; Wang JS; Hong CY Rheumatology (Oxford); 2012 Nov; 51(11):1953-65. PubMed ID: 22843790 [TBL] [Abstract][Full Text] [Related]
4. MEK/ERK and signal transducer and activator of transcription signaling pathways modulate oncostatin M-stimulated CCL2 expression in human osteoblasts through a common transcription factor. Lin SK; Kok SH; Yeh FT; Kuo MY; Lin CC; Wang CC; Goldring SR; Hong CY Arthritis Rheum; 2004 Mar; 50(3):785-93. PubMed ID: 15022320 [TBL] [Abstract][Full Text] [Related]
5. An extract of green tea, epigallocatechin-3-gallate, reduces periapical lesions by inhibiting cysteine-rich 61 expression in osteoblasts. Lee YL; Hong CY; Kok SH; Hou KL; Lin YT; Chen MH; Wang CC; Lin SK J Endod; 2009 Feb; 35(2):206-11. PubMed ID: 19166774 [TBL] [Abstract][Full Text] [Related]
7. Tea polyphenol (-)-epigallocatechin 3-gallate suppresses heregulin-beta1-induced fatty acid synthase expression in human breast cancer cells by inhibiting phosphatidylinositol 3-kinase/Akt and mitogen-activated protein kinase cascade signaling. Pan MH; Lin CC; Lin JK; Chen WJ J Agric Food Chem; 2007 Jun; 55(13):5030-7. PubMed ID: 17539658 [TBL] [Abstract][Full Text] [Related]
8. Epigallocatechin-3 gallate induces growth inhibition and apoptosis in human breast cancer cells through survivin suppression. Tang Y; Zhao DY; Elliott S; Zhao W; Curiel TJ; Beckman BS; Burow ME Int J Oncol; 2007 Oct; 31(4):705-11. PubMed ID: 17786300 [TBL] [Abstract][Full Text] [Related]
9. Catechins inhibit CXCL10 production from oncostatin M-stimulated human gingival fibroblasts. Hosokawa Y; Hosokawa I; Ozaki K; Nakanishi T; Nakae H; Matsuo T J Nutr Biochem; 2010 Jul; 21(7):659-64. PubMed ID: 19616927 [TBL] [Abstract][Full Text] [Related]
10. Regulation of interleukin-1beta-induced chemokine production and matrix metalloproteinase 2 activation by epigallocatechin-3-gallate in rheumatoid arthritis synovial fibroblasts. Ahmed S; Pakozdi A; Koch AE Arthritis Rheum; 2006 Aug; 54(8):2393-401. PubMed ID: 16869002 [TBL] [Abstract][Full Text] [Related]
11. (-)-Epigallocatechin-3-gallate inhibits monocyte chemotactic protein-1 expression in endothelial cells via blocking NF-kappaB signaling. Hong MH; Kim MH; Chang HJ; Kim NH; Shin BA; Ahn BW; Jung YD Life Sci; 2007 May; 80(21):1957-65. PubMed ID: 17379255 [TBL] [Abstract][Full Text] [Related]
12. (-)-Epigallocatechin gallate reduces transforming growth factor beta-stimulated HSP27 induction through the suppression of stress-activated protein kinase/c-Jun N-terminal kinase in osteoblasts. Hayashi K; Takai S; Matsushima-Nishiwaki R; Hanai Y; Kato K; Tokuda H; Kozawa O Life Sci; 2008 May; 82(19-20):1012-7. PubMed ID: 18407296 [TBL] [Abstract][Full Text] [Related]
13. Phosphatidylinositol-3 kinase/Akt and GSK-3 mediated cytoprotective effect of epigallocatechin gallate on oxidative stress-injured neuronal-differentiated N18D3 cells. Koh SH; Kim SH; Kwon H; Kim JG; Kim JH; Yang KH; Kim J; Kim SU; Yu HJ; Do BR; Kim KS; Jung HK Neurotoxicology; 2004 Sep; 25(5):793-802. PubMed ID: 15288510 [TBL] [Abstract][Full Text] [Related]
14. (-)-Epigallocatechin-3-gallate suppresses osteoclast differentiation and ameliorates experimental arthritis in mice. Morinobu A; Biao W; Tanaka S; Horiuchi M; Jun L; Tsuji G; Sakai Y; Kurosaka M; Kumagai S Arthritis Rheum; 2008 Jul; 58(7):2012-8. PubMed ID: 18576345 [TBL] [Abstract][Full Text] [Related]
15. Naringin-induced bone morphogenetic protein-2 expression via PI3K, Akt, c-Fos/c-Jun and AP-1 pathway in osteoblasts. Wu JB; Fong YC; Tsai HY; Chen YF; Tsuzuki M; Tang CH Eur J Pharmacol; 2008 Jul; 588(2-3):333-41. PubMed ID: 18495116 [TBL] [Abstract][Full Text] [Related]
16. Pro-apoptotic effect of epigallo-catechin-3-gallate on B lymphocytes through regulating BAFF/PI3K/Akt/mTOR signaling in rats with collagen-induced arthritis. Liu D; Li P; Song S; Liu Y; Wang Q; Chang Y; Wu Y; Chen J; Zhao W; Zhang L; Wei W Eur J Pharmacol; 2012 Sep; 690(1-3):214-25. PubMed ID: 22760071 [TBL] [Abstract][Full Text] [Related]
17. [Epigallocatechin-3-gallate interferes with EBV-encoding AP-1 signal transduction pathway]. Zhao Y; Wang H; Zhao XR; Luo FJ; Tang M; Cao Y Zhonghua Zhong Liu Za Zhi; 2004 Jul; 26(7):393-7. PubMed ID: 15355641 [TBL] [Abstract][Full Text] [Related]
18. Simvastatin inhibits cytokine-stimulated Cyr61 expression in osteoblastic cells: a therapeutic benefit for arthritis. Kok SH; Hou KL; Hong CY; Wang JS; Liang PC; Chang CC; Hsiao M; Yang H; Lai EH; Lin SK Arthritis Rheum; 2011 Apr; 63(4):1010-20. PubMed ID: 20191585 [TBL] [Abstract][Full Text] [Related]
19. Epigallocatechin gallate (EGCG) attenuates high glucose-induced insulin signaling blockade in human hepG2 hepatoma cells. Lin CL; Lin JK Mol Nutr Food Res; 2008 Aug; 52(8):930-9. PubMed ID: 18496818 [TBL] [Abstract][Full Text] [Related]
20. Regulation of urokinase plasminogen activator by epigallocatechin-3-gallate in human fibrosarcoma cells. Kim MH; Jung MA; Hwang YS; Jeong M; Kim SM; Ahn SJ; Shin BA; Ahn BW; Jung YD Eur J Pharmacol; 2004 Mar; 487(1-3):1-6. PubMed ID: 15033370 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]